Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection

European Journal of Ophthalmology

Volumn 23, Issue 3, 2013, Pages 277-283

  El Chehab, Hussam ^a   Le Corre, Anne ^a   Agard, Emilie ^a   Ract Madoux, Guillaume ^a   Coste, Olivier ^a   Dot, Corinne ^a  

^a HIA Desgenettes   (France)

Author keywords

Anti vascular endothelial growth factor; Intraocular pressure; Intravitreal injection; IOP lowering medications

Indexed keywords

ACETAZOLAMIDE; APRACLONIDINE; BIMATOPROST; BRIMONIDINE PLUS TIMOLOL; BRINZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; RANIBIZUMAB; TIMOLOL; TRAVOPROST;

AGE; AGED; ANALYSIS OF VARIANCE; APHAKIA; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EYE AXIS LENGTH; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; POST HOC ANALYSIS; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PSEUDOPHAKIA; RETINA MACULA AGE RELATED DEGENERATION; TONOMETRY; TREATMENT OUTCOME;

ACETAZOLAMIDE; ADMINISTRATION, TOPICAL; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIHYPERTENSIVE AGENTS; CLONIDINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; QUINOXALINES; SULFONAMIDES; THIOPHENES; TIMOLOL; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84876565194     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000159     Document Type: Article

References (23)

1. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hil-lemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond) 2009; 23: 181-5.
2. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008; 146: 930-4.
3. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44.
4. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR; MARINA Study Group. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007; 125: 1460-9.
5. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148: 43-58.
6. Theoulakis PE, Lepidas J, Petropoulos IK, Livieratou A, Brinkmann CK, Katsimpris JM. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd 2010; 227: 280-4.
7. Frenkel M P, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol 2010; 128: 1523-7.
8. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007; 42: 807-11.
9. Kerimoglu H, Ozturk BT, Bozkurt B, Okka M, Okudan S. Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? Acta Ophthalmol 2011; 89: 138-42.
10. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Short-term effect of intravitreal injection of Ranibizumab (Lu-centis) on intraocular pressure. J Glaucoma 2009; 18: 658-61.
11. Silverstone DE, Brint SF, Olander KW, et al. Prophylactic use of apraclonidine for intraocular pressure increase after Nd: YAG capsulotomies. Am J Ophthalmol 1992; 113: 401-5.
12. Jampel HD, Robin AL, Quigley HA, Pollack I P. Apraclonidine: a one-week dose-response study. Arch Ophthalmol 1988; 106: 1069-73.
13. Friedland BR, Mallonee J, Anderson DR. Short-term dose response characteristics of acetazolamide in man. Arch Ophthalmol 1977; 95: 1809-12.
14. Chan KC, Poostchi A, Wong T, Insull EA, Sachdev N, Wells A P. Visual field changes after transient elevation of intraocular pressure in eyes with and without glaucoma. Ophthalmology 2008; 115: 667-72.
15. Bushley DM, Parmley VC, Paglen P. Visual field defect associated with laser in situ keratomileusis. Am J Ophthalmol 2000; 129: 668-71.
16. Hirata A, Yonemura N, Hasumura T, Murata Y, Negi A. Effect of infusion air pressure on visual field defects after macular hole surgery. Am J Ophthalmol 2000; 130: 611-6.
17. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Linden-muth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9: 134-42.
18. Joos KM, Kay MD, Pillunat LE, et al. Effect of acute intraocular pressure changes on short posterior ciliary artery haemo-dynamics. Br J Ophthalmol 1999; 83: 33-8.
19. Kong YX, Crowston JG, Vingrys AJ, Trounce IA, Bui VB. Functional changes in the retina during and after acute intraocular pressure elevation in mice. Invest Ophthalmol Vis Sci 2009; 50: 5732-40.
20. He Z, Bui BV, Vingrys AJ. The rate of functional recovery from acute IOP elevation. Invest Ophthalmol Vis Sci 2006; 47: 4872-80.
21. Yang H, Thompson H, Roberts MD, Sigal IA, Downs JC, Bur-goyne C F. Deformation of the early glaucomatous monkey optic nerve head connective tissue after acute IOP elevation in 3-D histomorphometric reconstructions. Invest Ophthal-mol Vis Sci 2011; 52: 345-63.
22. Sigal IA, Flanagan JG, Tertinegg I, Ethier CR. Modeling individual-specific human optic nerve head biomechanics: Part I: IOP-induced deformations and influence of geometry. Bio-mech Model Mechanobiol 2009; 8: 85-98.
23. Poostchi A, Wong T, Chan KC, et al. Optic disc diameter increases during acute elevations of intraocular pressure. Invest Ophthalmol Vis Sci 2010; 51: 2313-6.